An abundance of noninvasive scores have been associated with fibrosis and hepatocellular carcinoma (HCC) development. We aimed to compare the prognostic ability of these scores in relation to liver histology in chronic hepatitis B (CHB) patients. Liver biopsies from treatment-naïve CHB patients at one tertiary care centre were scored by a single hepato-pathologist. Laboratory values at liver biopsy were used to calculate the 
| INTRODUCTION
Approximately 350 million patients worldwide have chronic hepatitis B (CHB). Long-term CHB can lead to liver cirrhosis, decompensation, hepatocellular carcinoma (HCC) development and death. Nearly 30% of cirrhosis and 53% of all HCC is attributable to CHB, and about 650 000 patients die to the complications of CHB each year.
1,2 Disease progression may be halted by antiviral therapy (AVT), and therefore, it is important to assess the risk of deterioration for individual patients to be able to provide a timely intervention for those who benefit most. [3] [4] [5] For decades, liver biopsy has been the gold standard to assess the severity of liver disease and the patients' related prognosis.
However, this procedure is associated with potentially severe complications, sampling error, as well as inter-and intra-observer variation. 6, 7 Noninvasive objective surrogate scores for the long-term prognosis are therefore warranted.
Recently, the FIB-4 and APRI scores have been developed to estimate the fibrosis severity with moderate to good accuracy, and the FIB-4 score has additionally been associated with survival and HCC development during 5 years of follow-up. [8] [9] [10] [11] [12] Furthermore, the PAGE-B score has been developed to estimate the probability of HCC development in Caucasian CHB patients treated with entecavir or tenofovir, as an alternative to the REACH-B, CU-HCC and GAG-HCC scores which were only associated with HCC development in Asian patients. [13] [14] [15] [16] [17] [18] It is unknown how the prognostic accuracy of these noninvasive serum scores compares to that of liver histology with respect to the long-term outcome in CHB patients, especially with regard to event-free and transplant-free survival. Also, the prognostic benefit in performing a liver biopsy in addition to these noninvasive scores has, to our knowledge, not been assessed in detail.
The aims of the current study therefore were (i) to assess the prognostic performance of simple noninvasive risk scores in different subgroups, and (ii) to assess whether liver histological characteristics could improve this performance in CHB patients.
| MATERIALS AND METHODS

| Patient selection
The patient population and selection have been described previously. 19 In short, mono-infected treatment-naïve CHB (HBsAg posi- 
| Data acquisition
Data on all-cause mortality were obtained from the municipal record database, and the development of HCC was obtained from the national HCC registry database. 
| Liver histology
All liver biopsies were obtained percutaneously. 
| Laboratory measurements
The gender and time-dependent upper limit of normal values were used for the analysis of serum ALT and AST. The HBV DNA level was expressed in units/millilitre (IU/mL) and, when required, calculated using the conversion of 1.0 pg/mL=5.15 × 10 4 IU/mL or 1.0 copies/ mL=0.1818 IU/mL. HBV genotype was determined using the INNOLiPA Genotype assay (Innogenetics, Ghent, Belgium) in case data on HBV genotype were missing. 
| Outcome measures
| Statistical analysis
Baseline was defined as the date of first liver biopsy. Scores for cirrhosis and outcome were constructed as previously described and their respective cut-offs were utilized in the analysis when appropriate ( Table 1) 
26,27
Skewed variables were log-transformed prior to the analyses. SPSS version 22.0 (SPSS Inc., Chicago, IL, USA) and the SAS 9.3 program (SAS Institute Inc., Cary, NC, USA) were used to perform statistical analyses. All statistical tests were two-sided and evaluated at the .05 level of significance. INNO-LiPA assays were provided by Innogenetics (Belgium). The funding sources did not have influence on study design, data collection, analysis and interpretation of the data, writing of the report or the decision to submit for publication.
| Role of the funding source
| RESULTS
| Patient characteristics
Of 880 biopsied CHB patients, 163 did not meet eligibility criteria, 127 were excluded because of a missing chart or liver biopsy and 33 were excluded because of an inadequate liver biopsy sample. In total, 557 patients were thus included, of which 371 (67%) were male.
The mean age at biopsy was 34.7 years. Patient characteristics are presented in Table 2 . 47% of patients were Caucasian (n=261), 31%
Asian (n=175) and 19% African (n=104 
| Events during follow-up
The mean duration of follow-up after liver biopsy was 10. patients, the cause of death was unknown. The overall 5-, 10-and 20-year event-free survival was 97.6%, 94.0% and 86.8%, respectively.
| Factors associated with long-term clinical outcome
Fifty-five per cent (22/40) of all patients with an event had advanced fibrosis at baseline. The (non-)invasive scores were all significantly associated with the development of a clinical event, HCC and a reduced transplant-free survival (Table S1 ). In addition to the Ishak 
| Noninvasive scores vs liver biopsy for the prediction of clinical outcome
The C-statistic for the PAGE-B score for the prediction of any clinical event was .86 (95% CI: 0.80-0.92, Table 3 and 61.2% at year 15, respectively (log-rank P<.001, Figure 1 ). The estimated event risk and HCC risk for individual patients using the PAGE-B score are shown in Figure 2 . For patients with a PAGE-B score <10, 10-17 and >17, the estimated 5-year event risk was <0.7%, 0.7%-8.0% and ≥8.0%; the 10-year event risk <1.5%, 1.5%-17.5% and ≥17.5%; and the 15-year event risk <3.0%, 3.0%-32.0%
and ≥32%, respectively.
| Performance of noninvasive risk scores for clinical outcome in subgroups
For the prediction of any clinical event, the PAGE-B had the overall highest C-statistic compared to the other noninvasive scores stratified by AVT, advanced fibrosis and ethnicity (Table 4) (13%) patients were correctly reclassified into the low-risk group by addition of the Ishak score, and no patients were incorrectly reclassified (total NRI=.134).
Using the same method, we also assessed the NRI for HCC predic- 
| DISCUSSION
In the current study, we have compared different prognostic scores for their ability to predict the clinical outcome over more than The GAG-HCC and CU-HCC scores already include the diagnosis of cirrhosis, which in the current study is solely based on liver biopsy, and are therefore "invasive markers". In bold, the noninvasive or invasive marker with the highest C-statistic.
T A B L E 3 C-statistic for the prediction of clinical outcome by prognostic biomarkers The GAG-HCC and CU-HCC scores already include the diagnosis of cirrhosis, which in the current study is solely based on liver biopsy, and are therefore "invasive markers." AVT, antiviral therapy. In bold, the noninvasive or invasive marker with the highest C-statistic.
For decades, the gold standard to assess the severity of liver disease has been liver biopsy. 7 With the combination of the PAGE-B score and the Ishak stage, the long-term risk prediction improved only minimally (from a C-statistic of .86 to .87). It could be debated whether the slight improvement in the detection of events justifies a liver biopsy with its accompanying risk for potentially severe complications, observer and sampling limitations, while the PAGE-B score is an objective, readily available and relative simple risk score.
A strength of the current study is that all liver biopsies were scored by a single experienced hepato-pathologist, which excludes interobserver and also minimizes intra-observer variation. 23 Moreover, the long-term follow-up data were both obtained from the municipal record database as well as from the national HCC registry database. As a result, data on HCC development and survival were complete for 93% of the cohort. We were not able to assess the effect of AVT on outcome because of different AVT regimens, different response criteria and significant differences between patients who were or were not treated. Although this is an important question, this analysis was outside the scope of this article, and more importantly, we have shown that the PAGE-B score had the best predictive ability for treated or untreated patients separately. Furthermore, we could not obtain repeated measurements to evaluate the longitudinal behaviour of the risk scores, and did not have data on transient elastography or HBsAg levels. It would be important to assess the added value of these factors to the PAGE-B score in future research. [28] [29] [30] [31] In conclusion, we have shown that the PAGE-B score was the best performing noninvasive score to predict the clinical outcome of CHB patients of different origin and within different subgroups. The
Ishak stage did not clinically improve the risk prediction of the PAGE-B score. When further validated, this score could additionally be used to assess the need for AVT and HCC surveillance.
